Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free ELVN Stock Alerts

Enliven Therapeutics (ELVN) Financials

Enliven Therapeutics logo
$50.24 +1.12 (+2.28%)
Closing price 04:00 PM Eastern
Extended Trading
$50.02 -0.22 (-0.44%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Enliven Therapeutics

Annual Income Statements for Enliven Therapeutics

This table shows Enliven Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -23 -49 -51 -38 -72 -89 -104
Consolidated Net Income / (Loss)		 -23 -41 -51 -38 -72 -89 -104
Net Income / (Loss) Continuing Operations		 -23 -41 -51 -38 -72 -90 -104
Total Pre-Tax Income 		-23 -41 -51 -38 -72 -90 -104
Total Operating Income		 -24 -42 -51 -39 -84 -105 -120
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 24 42 51 39 84 105 120
Selling, General & Admin Expense		 5.11 9.54 13 7.77 19 24 34
Research & Development Expense		 19 32 38 31 65 81 86
Total Other Income / (Expense), net		 0.65 0.34 0.06 1.13 12 16 16
Interest & Investment Income		 0.58 0.48 0.23 1.13 12 15 16
Other Income / (Expense), net		 0.08 -0.15 -0.18 0.00 -0.02 -0.00 -0.05
Income Tax Expense		 - - 0.00 - 0.00 0.23 0.00
Basic Earnings per Share		 ($33.40) ($49,218,003.53) ($2.37) ($12.05) ($2.01) ($1.89) ($1.83)
Weighted Average Basic Shares Outstanding		 702.46K 13.92M 21.66M 3.12M 35.55M 47.07M 56.66M
Diluted Earnings per Share		 ($33.40) ($49,218,003.53) ($2.37) ($12.05) ($2.01) ($1.89) ($1.83)
Weighted Average Diluted Shares Outstanding		 702.46K 13.92M 21.66M 3.12M 35.55M 47.07M 56.66M
Weighted Average Basic & Diluted Shares Outstanding		 702.46K 13.92M 21.66M 26.23M 41.35M 49.00M 59.80M

Quarterly Income Statements for Enliven Therapeutics

This table shows Enliven Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24 -32
Consolidated Net Income / (Loss)		 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24 -32
Net Income / (Loss) Continuing Operations		 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24 -32
Total Pre-Tax Income 		-19 -23 -20 -23 -23 -29 -25 -20 -30 -24 -32
Total Operating Income		 -23 -26 -25 -27 -27 -32 -29 -25 -34 -28 -37
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 23 26 25 27 27 32 29 25 34 28 37
Selling, General & Admin Expense		 4.82 6.02 5.78 5.81 6.17 6.80 7.09 6.87 13 7.14 8.21
Research & Development Expense		 18 20 19 21 21 25 21 18 21 21 29
Total Other Income / (Expense), net		 3.36 3.25 4.65 3.91 3.48 3.15 3.25 4.95 4.62 4.20 4.72
Interest & Investment Income		 3.37 3.25 4.09 3.84 3.72 3.20 3.25 4.95 4.62 4.20 4.73
Other Income / (Expense), net		 -0.01 -0.00 0.80 0.07 - -0.05 -0.00 0.00 - 0.00 -0.01
Basic Earnings per Share		 ($0.29) ($0.54) ($0.41) ($0.48) ($0.46) ($0.57) ($0.49) ($0.32) ($0.45) ($0.38) ($0.49)
Weighted Average Basic Shares Outstanding		 35.55M 42.05M 48.08M 48.27M 47.07M 50.05M 52.11M 62.09M 56.66M 62.80M 66.17M
Diluted Earnings per Share		 ($0.29) ($0.54) ($0.41) ($0.48) ($0.46) ($0.57) ($0.49) ($0.32) ($0.45) ($0.38) ($0.49)
Weighted Average Diluted Shares Outstanding		 35.55M 42.05M 48.08M 48.27M 47.07M 50.05M 52.11M 62.09M 56.66M 62.80M 66.17M
Weighted Average Basic & Diluted Shares Outstanding		 41.35M 47.04M 47.24M 48.86M 49.00M 49.07M 59.24M 59.35M 59.80M 60.90M 73.27M

Annual Cash Flow Statements for Enliven Therapeutics

This table details how cash moves in and out of Enliven Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.36 43 0.70 -34 25 24 -25
Net Cash From Operating Activities		 -22 -37 -47 -32 -61 -73 -70
Net Cash From Continuing Operating Activities		 -22 -37 -47 -32 -61 -73 -70
Net Income / (Loss) Continuing Operations		 -23 -41 -51 -38 -72 -89 -104
Consolidated Net Income / (Loss)		 -23 -41 -51 -38 -72 -89 -104
Depreciation Expense		 0.03 0.10 0.10 0.22 0.30 0.32 0.26
Amortization Expense		 -0.02 0.12 0.16 0.00 -4.60 0.42 -0.23
Non-Cash Adjustments To Reconcile Net Income		 0.90 2.23 3.87 4.93 13 20 34
Changes in Operating Assets and Liabilities, net		 0.67 1.51 0.51 0.44 1.40 -4.54 -1.12
Net Cash From Investing Activities		 -24 -17 -1.63 -0.61 -148 -36 -174
Net Cash From Continuing Investing Activities		 -24 -17 -1.63 -0.61 -148 -36 -174
Purchase of Property, Plant & Equipment		 -0.14 -0.02 -0.01 -0.61 -0.15 -0.04 -0.16
Purchase of Investments		 -24 -64 -48 0.00 -268 -351 -447
Sale of Property, Plant & Equipment		 - - 0.00 - - 0.00 0.21
Sale and/or Maturity of Investments		 0.00 48 46 0.00 120 314 273
Other Investing Activities, net		 - - - - 0.00 0.87 0.00
Net Cash From Financing Activities		 44 97 49 -1.80 234 133 219
Net Cash From Continuing Financing Activities		 44 97 49 -1.80 235 133 219
Issuance of Common Equity		 0.00 80 1.82 0.00 161 130 217
Other Financing Activities, net		 0.00 1.02 0.86 -1.80 82 3.63 2.08
Cash Income Taxes Paid		 - - - - 0.00 0.23 0.00

Quarterly Cash Flow Statements for Enliven Therapeutics

This table details how cash moves in and out of Enliven Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 26 49 -52 3.75 23 -22 18 -18 -2.84 33 3.32
Net Cash From Operating Activities		 -12 -23 -20 -12 -17 -24 -17 -13 -16 -19 -19
Net Cash From Continuing Operating Activities		 -12 -23 -20 -12 -17 -24 -17 -13 -16 -19 -19
Net Income / (Loss) Continuing Operations		 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24 -32
Consolidated Net Income / (Loss)		 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24 -32
Depreciation Expense		 0.08 0.08 0.08 0.08 0.08 0.07 0.08 0.06 0.05 0.01 0.01
Amortization Expense		 -1.79 -0.66 -0.60 0.71 0.98 -0.05 0.07 -0.31 0.06 0.27 0.51
Non-Cash Adjustments To Reconcile Net Income		 3.13 4.59 4.42 5.18 5.43 6.88 7.81 7.27 13 7.49 14
Changes in Operating Assets and Liabilities, net		 5.46 -4.64 -4.38 4.99 -0.51 -2.50 0.31 -0.16 1.22 -3.43 -0.61
Net Cash From Investing Activities		 39 -18 -34 15 0.73 1.43 -184 -4.06 12 43 -442
Net Cash From Continuing Investing Activities		 39 -18 -34 15 0.73 1.43 -184 -4.06 12 43 -442
Purchase of Property, Plant & Equipment		 -0.01 -0.02 -0.00 -0.02 - -0.02 -0.14 0.00 - 0.00 -0.10
Purchase of Investments		 -41 -57 -121 -57 -117 -59 -240 -72 -76 -66 -560
Sale and/or Maturity of Investments		 80 39 77 81 117 61 57 68 88 108 119
Net Cash From Financing Activities		 0.09 90 1.81 1.12 40 0.23 218 -0.37 0.62 10 463
Net Cash From Continuing Financing Activities		 0.65 90 1.81 1.12 40 0.23 218 -0.37 0.62 10 463
Other Financing Activities, net		 0.65 0.27 1.79 1.12 0.45 0.23 1.32 0.09 0.43 10 30

Annual Balance Sheets for Enliven Therapeutics

This table presents Enliven Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 33 91 94 83 272 326 476
Total Current Assets		 31 90 93 78 266 318 475
Cash & Equivalents		 4.94 48 48 76 100 124 99
Short-Term Investments		 24 41 42 0.00 153 189 364
Prepaid Expenses		 1.72 2.18 2.42 2.22 2.95 4.63 12
Plant, Property, & Equipment, net		 0.44 0.35 0.25 0.89 0.74 0.46 0.03
Total Noncurrent Assets		 2.23 0.09 0.70 4.66 4.97 7.18 1.26
Other Noncurrent Operating Assets		 2.23 0.09 0.70 4.66 4.97 7.18 1.26
Total Liabilities & Shareholders' Equity		 33 91 94 83 272 326 476
Total Liabilities		 4.38 6.41 7.62 10 26 16 17
Total Current Liabilities		 4.20 6.25 7.21 9.72 26 16 17
Accounts Payable		 1.66 1.97 2.36 3.44 0.53 1.34 2.16
Accrued Expenses		 2.54 4.28 4.60 6.28 15 15 14
Total Noncurrent Liabilities		 0.18 0.16 0.41 0.66 0.07 0.00 0.00
Other Noncurrent Operating Liabilities		 - 0.00 0.41 0.66 0.07 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -49 84 86 73 246 310 460
Total Preferred & Common Equity		 -49 84 86 -77 246 310 460
Preferred Stock		 0.00 0.00 0.00 150 0.00 0.00 0.00
Total Common Equity		 -49 84 86 -77 246 310 460
Common Stock		 5.87 181 234 6.04 400 553 806
Retained Earnings		 -55 -96 -147 -83 -154 -243 -347
Accumulated Other Comprehensive Income / (Loss)		 0.03 0.00 -0.02 0.00 0.14 0.06 0.33

Quarterly Balance Sheets for Enliven Therapeutics

This table presents Enliven Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 303 289 274 343 327 305 303 504 491 465 910
Total Current Assets		 298 283 269 337 318 297 294 496 483 463 907
Cash & Equivalents		 292 126 74 149 97 101 102 119 102 132 136
Short-Term Investments		 - 152 190 171 216 191 188 371 376 320 760
Prepaid Expenses		 5.90 5.31 5.13 6.64 5.68 5.11 4.76 5.12 5.12 11 12
Plant, Property, & Equipment, net		 0.85 0.87 0.81 0.68 0.63 0.55 0.40 0.46 0.40 0.02 0.14
Total Noncurrent Assets		 4.01 4.46 4.63 4.90 8.29 7.88 7.85 7.80 7.79 1.70 2.74
Other Noncurrent Operating Assets		 4.01 4.46 4.63 4.90 8.29 7.88 7.85 7.80 7.79 1.70 2.74
Total Liabilities & Shareholders' Equity		 303 289 274 343 327 305 303 504 491 465 910
Total Liabilities		 11 9.51 12 25 22 17 14 15 15 11 15
Total Current Liabilities		 11 9.15 12 25 22 17 14 15 15 11 14
Accounts Payable		 5.86 2.84 1.49 2.73 1.08 1.02 1.56 2.35 1.43 1.64 0.37
Accrued Expenses		 5.08 6.30 11 12 12 16 12 13 13 9.85 14
Total Noncurrent Liabilities		 0.51 0.36 0.21 0.03 0.01 0.00 0.30 0.20 0.10 0.00 0.91
Other Noncurrent Operating Liabilities		 0.51 0.36 0.21 0.03 0.01 0.00 0.30 0.20 0.10 - 0.91
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 291 279 262 318 305 288 288 488 476 453 895
Total Preferred & Common Equity		 291 279 262 318 305 288 288 488 476 453 895
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 291 279 262 318 305 288 288 488 476 453 895
Common Stock		 389 393 397 495 502 508 560 786 793 825 1,300
Retained Earnings		 -98 -114 -135 -177 -197 -220 -272 -297 -317 -371 -403
Accumulated Other Comprehensive Income / (Loss)		 - -0.11 -0.15 -0.05 -0.14 0.24 -0.02 -0.18 0.22 -0.38 -1.91

Annual Metrics And Ratios for Enliven Therapeutics

This table displays calculated financial ratios and metrics derived from Enliven Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - 59,347,317.00
DEI Adjusted Shares Outstanding		 - - - - - - 59,347,317.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -1.75
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -17 -29 -36 -27 -58 -73 -84
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -23.78% -23.62% -18.22%
Earnings before Interest and Taxes (EBIT)		 -24 -42 -52 -39 -84 -104 -120
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -42 -51 -39 -88 -103 -120
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 -36 -29 -54 -77 -84
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.01 -3.79 -4.25 -2.61 -7.30 -3.65 -3.02
Increase / (Decrease) in Invested Capital		 0.00 -3.80 -0.46 1.64 -4.68 3.65 0.63
Book Value per Share		 ($69.54) $4.85 $3.27 ($2.92) $5.97 $6.34 $7.74
Tangible Book Value per Share		 ($69.54) $4.85 $3.27 ($2.92) $5.97 $6.34 $7.74
Total Capital		 29 84 86 73 246 310 460
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -29 -88 -90 -76 -253 -313 -463
Capital Expenditures (CapEx)		 0.14 0.02 0.01 0.61 0.15 0.04 -0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.48 -4.06 -4.79 -7.50 -13 -11 -4.31
Debt-free Net Working Capital (DFNWC)		 26 84 85 68 240 302 458
Net Working Capital (NWC)		 26 84 85 68 240 302 458
Net Nonoperating Expense (NNE)		 6.58 12 15 11 13 16 20
Net Nonoperating Obligations (NNO)		 -29 -88 -90 -76 -253 -313 -463
Total Depreciation and Amortization (D&A)		 0.01 0.22 0.25 0.22 -4.31 0.74 0.04
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.53) ($51,384,002.37) $0.06 ($2.01) ($1.89) ($1.83)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 17.58M 26.29M 26.29M 35.55M 47.07M 56.66M
Adjusted Diluted Earnings per Share		 $0.00 ($3.53) ($51,384,002.37) $0.06 ($2.01) ($1.89) ($1.83)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 17.58M 26.29M 26.39M 35.55M 47.07M 56.66M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($3.53) ($51,384,002.37) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.92M 21.66M 26.23M 41.35M 49.00M 59.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -29 -36 -27 -58 -73 -84
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Enliven Therapeutics

This table displays calculated financial ratios and metrics derived from Enliven Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 59,347,317.00 59,800,406.00 60,904,946.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 59,347,317.00 59,800,406.00 60,904,946.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.50 -0.40 -0.53
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Growth		 -142.08% -62.50% -16.46% -0.14% -5.69% -19.35% -16.86% 3.28% - 13.14% -29.08%
EBIT Growth		 -123.73% -58.29% -18.23% -11.27% -18.29% -22.13% -20.09% 7.03% - 12.34% -30.19%
NOPAT Growth		 -123.64% -58.28% -22.20% -11.63% -18.33% -21.96% -16.18% 7.29% - 12.21% -30.17%
Net Income Growth		 -102.83% -54.43% -19.31% -11.49% -19.67% -25.53% -26.99% 12.99% - 17.23% -28.22%
EPS Growth		 90.03% 32.50% 0.00% 5.88% -58.62% -5.56% -19.51% 33.33% - 33.33% 0.00%
Operating Cash Flow Growth		 -53.25% -12.08% -69.60% 23.29% -37.82% -3.28% 16.53% -8.91% - 20.04% -8.64%
Free Cash Flow Firm Growth		 -28.30% -41.93% 39.56% -20.55% -100.19% -48.29% -197.05% -14.06% - 8.72% -10.13%
Invested Capital Growth		 -179.33% -314.87% -765.37% -101.45% 49.99% 55.76% 72.96% 58.59% - 176.57% 99.70%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Q/Q Growth		 6.57% -8.68% 8.43% -7.70% 1.39% -22.72% 10.34% 10.86% - 19.43% -33.24%
EBIT Q/Q Growth		 6.28% -14.29% 8.40% -13.41% 0.37% -18.01% 9.94% 12.21% - 18.85% -33.76%
NOPAT Q/Q Growth		 6.26% -14.33% 5.33% -10.02% 0.64% -17.84% 9.81% 12.20% - 18.85% -33.73%
Net Income Q/Q Growth		 6.74% -17.39% 12.26% -16.07% -0.10% -23.14% 11.24% 20.47% - 20.36% -37.49%
EPS Q/Q Growth		 43.14% -86.21% 24.07% -17.07% 4.17% -23.91% 14.04% 34.69% - 15.56% -28.95%
Operating Cash Flow Q/Q Growth		 21.47% -87.16% 12.53% 40.33% -41.09% -40.25% 29.30% 22.15% - -21.80% 3.94%
Free Cash Flow Firm Q/Q Growth		 21.28% -42.80% 46.47% -100.35% -30.72% -5.78% -7.23% 23.07% - 11.89% -29.37%
Invested Capital Q/Q Growth		 -321.73% 60.99% -163.95% 53.61% -4.71% 65.50% -61.32% 28.95% - 131.91% -100.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 101.18% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Interest Burden Percent		 85.19% 87.49% 82.83% 85.78% 86.18% 89.93% 88.63% 80.28% - 84.92% 87.29%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 -44.90% -26.14% -28.37% -30.98% -32.04% -31.30% -25.26% -25.43% - -26.64% -15.31%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -8,638.44% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Common Equity (ROCE)		 -23.81% -26.14% -28.37% -30.98% -32.04% -31.30% -25.26% -25.43% - -26.64% -15.31%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -25.05% -27.16% -29.55% 0.00% -32.89% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -18 -17 -19 -19 -22 -20 -18 -24 -19 -26
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.10% -1.48% -0.92% -1.52% -1.54% -2.08% -1.33% -0.67% - -1.12% -0.93%
Return On Investment Capital (ROIC_SIMPLE)		 -6.47% - - - -6.08% -7.70% -4.10% -3.69% -5.22% -4.30% -2.91%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -23 -26 -24 -27 -27 -32 -29 -25 -34 -28 -37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -27 -24 -26 -26 -32 -28 -25 -34 -28 -37
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.32 2.29 3.60 4.18 3.55 3.35 2.02 2.55 - 5.17 3.45
Price to Tangible Book Value (P/TBV)		 2.32 2.29 3.60 4.18 3.55 3.35 2.02 2.55 - 5.17 3.45
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 1,962.42 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Financial Leverage		 -1.03 -1.01 -1.01 -1.01 -1.02 -1.01 -1.01 -1.01 - -1.00 -1.00
Leverage Ratio		 1.11 1.06 1.05 1.05 1.08 1.06 1.05 1.04 - 1.03 1.02
Compound Leverage Factor		 0.95 0.93 0.87 0.90 0.93 0.96 0.93 0.84 - 0.88 0.89
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Altman Z-Score		 13.17 17.53 29.83 42.31 41.24 40.05 38.44 49.38 - 122.29 123.45
Noncontrolling Interest Sharing Ratio		 46.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 10.28 13.47 14.39 17.44 19.99 21.06 32.58 32.95 - 40.32 64.07
Quick Ratio		 9.78 12.80 14.13 17.14 19.69 20.72 32.25 32.60 - 39.38 63.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -16 -8.58 -17 -22 -24 -25 -20 -25 -22 -28
Operating Cash Flow to CapEx		 -89,157.14% -116,805.00% -1,021,750.00% -55,422.73% 0.00% -120,635.00% -12,271.22% 0.00% - 0.00% -18,718.18%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -7.30 -2.85 -7.51 -3.49 -3.65 -1.26 -2.03 -1.44 -3.02 0.96 -0.01
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.68 -2.16 -8.64 -1.76 3.65 1.59 5.48 2.04 0.63 2.22 2.03
Enterprise Value (EV)		 317 407 787 915 786 675 494 735 - 1,892 2,196
Market Capitalization		 570 727 1,099 1,206 1,099 964 984 1,213 - 2,344 3,091
Book Value per Share		 $5.97 $7.68 $6.48 $6.11 $6.34 $5.88 $9.95 $8.04 $7.74 $7.58 $14.70
Tangible Book Value per Share		 $5.97 $7.68 $6.48 $6.11 $6.34 $5.88 $9.95 $8.04 $7.74 $7.58 $14.70
Total Capital		 246 318 305 288 310 288 488 476 460 453 895
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -253 -321 -312 -292 -313 -290 -491 -478 -463 -452 -895
Capital Expenditures (CapEx)		 0.01 0.02 0.00 0.02 0.00 0.02 0.14 -0.00 0.00 0.00 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -8.39 -16 -12 -11 -9.21 -10 -9.53 -4.31 -0.75 -1.98
Debt-free Net Working Capital (DFNWC)		 240 312 296 280 302 280 480 468 458 452 893
Net Working Capital (NWC)		 240 312 296 280 302 280 480 468 458 452 893
Net Nonoperating Expense (NNE)		 3.46 4.55 2.73 4.21 4.35 6.36 5.33 2.58 5.67 4.15 6.44
Net Nonoperating Obligations (NNO)		 -253 -321 -312 -292 -313 -290 -491 -478 -463 -452 -895
Total Depreciation and Amortization (D&A)		 -1.71 -0.58 -0.53 0.79 1.06 0.03 0.15 -0.25 0.10 0.28 0.52
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.29) ($0.54) ($0.41) ($0.48) ($0.46) ($0.57) ($0.49) ($0.32) ($0.45) ($0.38) ($0.49)
Adjusted Weighted Average Basic Shares Outstanding		 35.55M 42.05M 48.08M 48.27M 47.07M 50.05M 52.11M 62.09M 56.66M 62.80M 66.17M
Adjusted Diluted Earnings per Share		 ($0.29) ($0.54) ($0.41) ($0.48) ($0.46) ($0.57) ($0.49) ($0.32) ($0.45) ($0.38) ($0.49)
Adjusted Weighted Average Diluted Shares Outstanding		 35.55M 42.05M 48.08M 48.27M 47.07M 50.05M 52.11M 62.09M 56.66M 62.80M 66.17M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 41.35M 47.04M 47.24M 48.86M 49.00M 49.07M 59.24M 59.35M 59.80M 60.90M 73.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -18 -17 -19 -19 -22 -20 -18 -24 -19 -26
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -12.20% -1.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 -12.20% -1.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Enliven Therapeutics (NASDAQ: ELVN) remains a development-stage biotechnology company with no reported revenue. Total revenue has been $0 in every quarterly income statement provided, while the company continues to fund research and development activities through equity financing and investment income.

The company’s financial position has strengthened substantially since 2022. Cash and short-term investments increased from approximately $91.7 million in Q2 2022 to $895.2 million in Q2 2026. However, this improvement has primarily come from capital raises rather than internally generated cash flow.

  • Large liquidity cushion: Cash and short-term investments totaled approximately $895.2 million at June 30, 2026, compared with just $277.9 million at June 30, 2023. This provides substantial funding for clinical development and general operations.
  • Low balance-sheet leverage: Total liabilities were only $15.1 million in Q2 2026 against $910.2 million of assets. The company reported no meaningful long-term debt, limiting interest-rate and refinancing risk.
  • Strong current ratio: Current assets of $907.3 million were approximately 64 times current liabilities of $14.2 million, indicating considerable short-term financial flexibility.
  • Investment income is helping offset operating losses: Interest and investment income increased to $4.7 million in Q2 2026 from $3.4 million in Q2 2023. The growing cash and investment portfolio is generating a modest but recurring source of non-operating income.
  • Recent financing materially extended the cash position: Enliven reported $463.4 million of financing cash inflow in Q2 2026, following $218.4 million in Q2 2025. These financings helped support the increase in cash and investments.
  • Investment cash flows are volatile but primarily reflect portfolio management: The company purchased $560.2 million of investments and received $118.7 million from investment sales or maturities in Q2 2026. The resulting $441.6 million investing cash outflow appears largely related to moving cash into short-term investments rather than funding property or equipment.
  • Operating cash burn has remained relatively consistent: Net cash used in operating activities was $18.5 million in Q2 2026, compared with $19.3 million in Q1 2026 and $17.1 million in Q2 2025. At the latest quarterly burn rate, the company’s liquid resources appear substantial, although future clinical spending could increase materially.
  • Losses continue to widen: Q2 2026 net loss increased to $32.5 million from $23.6 million in Q1 2026 and $25.3 million in Q2 2025. The company has reported a net loss in every period provided.
  • Research and development spending is accelerating: R&D expense reached $29.0 million in Q2 2026, up from $20.1 million in Q2 2024 and $15.2 million in Q2 2023. Higher development spending may support the pipeline, but it also increases the rate at which cash is consumed.
  • Shareholder dilution is a significant risk: Weighted-average basic shares outstanding rose to 66.2 million in Q2 2026 from 52.1 million in Q2 2025 and 3.1 million in Q2 2022. Repeated equity financing has strengthened the balance sheet but reduces existing investors’ ownership percentage and increases the shares over which future earnings would need to be distributed.
  • The company remains dependent on future financing or commercial success: Retained earnings were negative $403.3 million in Q2 2026, and operating activities have produced negative cash flow in every reported quarter. Without revenue or positive operating cash flow, long-term value creation depends on successful clinical development, eventual product commercialization, or additional capital raises.

Overall, ELVN has moved from a relatively small cash balance in 2022 to a well-capitalized balance sheet in Q2 2026. That is a positive near-term liquidity development, but the company’s core financial trend remains that of a loss-making biotechnology developer: revenue is still zero, R&D expenses are rising, operating cash flow is negative, and equity issuance has been the primary source of funding.

09/17/26 03:36 PM ETAI Generated. May Contain Errors.

Enliven Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Enliven Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Enliven Therapeutics' net income appears to be on an upward trend, with a most recent value of -$103.69 million in 2025, rising from -$23.46 million in 2019. The previous period was -$89.02 million in 2024. Check out Enliven Therapeutics' forecast to explore projected trends and price targets.

Enliven Therapeutics' total operating income in 2025 was -$119.66 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $119.66 million

Over the last 6 years, Enliven Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Enliven Therapeutics' total liabilities were at $16.57 million at the end of 2025, a 4.1% increase from 2024, and a 278.1% increase since 2019.

In the past 6 years, Enliven Therapeutics' cash and equivalents has ranged from $4.94 million in 2019 to $124.12 million in 2024, and is currently $98.90 million as of their latest financial filing in 2025.

Over the last 6 years, Enliven Therapeutics' book value per share changed from -69.54 in 2019 to 7.74 in 2025, a change of -111.1%.


Related Companies

Financial statements for NASDAQ:ELVN last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel